# MEF2A

## Overview
The MEF2A gene encodes the myocyte enhancer factor 2A, a transcription factor that is integral to the regulation of gene expression in muscle tissues and other cell types. As a member of the myocyte enhancer factor 2 (MEF2) family, MEF2A is characterized by a conserved MADS-box domain and an adjacent MEF2 domain, which are essential for its DNA-binding and dimerization capabilities (Wu2010Structure). The protein is predominantly expressed in skeletal, cardiac, and smooth muscles, as well as in neuronal cells and the endothelium of coronary arteries, where it plays a pivotal role in muscle differentiation, development, and regeneration (Guella2009Association). MEF2A's function is modulated by interactions with various co-activators and transcription factors, as well as by post-translational modifications and alternative splicing, which influence its transcriptional activity (Taylor2017Mef2). Clinically, mutations in the MEF2A gene have been associated with cardiovascular diseases such as coronary artery disease and dilated cardiomyopathy, highlighting its significance in maintaining cardiac health (Wang2005Molecular; Qiao2020Detection).

## Structure
The MEF2A protein is characterized by a conserved MADS-box domain and an adjacent MEF2 domain, which are crucial for its DNA-binding and dimerization functions. The primary structure of MEF2A includes key residues such as Gly2, Arg3, Lys4, Lys5, and Ile6, which are involved in DNA interaction (Wu2010Structure). The secondary structure features an extended N-terminal tail, three helices (H1, H2, H3), and three beta strands (β1, β2, β3) (Wu2010Structure). The tertiary structure reveals a hydrophobic groove that serves as a cofactor-binding site, bordered by a central beta sheet and helix H2 from each monomer (Wu2010Structure).

In terms of quaternary structure, MEF2A forms a dimer when bound to DNA, with each monomer contributing to a six-strand beta sheet sandwiched by helices (Wu2010Structure). The MEF2A-DNA complex is characterized by a 2-fold symmetric dimer interface, involving the MADS-box and MEF2S domain (Huang2000Solution). MEF2A does not significantly bend DNA, unlike the related SRF protein, due to differences in amino acid composition (Santelli2000Crystal). The protein can undergo post-translational modifications such as phosphorylation, which influence its activity. MEF2A also has splice variant isoforms that may affect its function and interactions.

## Function
MEF2A is a transcription factor that plays a crucial role in muscle differentiation and development. It is part of the myocyte enhancer factor 2 (MEF2) family, which is involved in regulating gene expression in muscle tissues. MEF2A is highly expressed in skeletal, cardiac, and smooth muscles, as well as in neuronal cells and the endothelium of coronary arteries (Guella2009Association). In muscle cells, MEF2A interacts with myogenic regulatory factors (MRFs) to enhance muscle differentiation by synergistically activating gene expression (Taylor2017Mef2).

MEF2A is involved in the regulation of muscle fiber characteristics, such as size, contractile speed, and metabolic properties. It promotes the slow oxidative fiber type by cooperating with activated calcineurin protein phosphatase to activate enhancer elements preferentially expressed in slow/oxidative muscles (Taylor2017Mef2). MEF2A also plays a role in muscle regeneration, although its function can be compensated by other MEF2 factors, such as MEF2C and MEF2D, in the absence of injury (Liu2014Requirement).

MEF2A is active in the nucleus, where it binds to DNA sequences to regulate the transcription of target genes involved in muscle structure, adhesion, fusion, and neuromuscular junction assembly (Taylor2017Mef2). Its activity is modulated by alternative splicing and post-translational modifications, which can enhance or repress its transcriptional activity (Taylor2017Mef2).

## Clinical Significance
Mutations in the MEF2A gene have been implicated in several cardiovascular diseases. A 21-basepair deletion in exon 11 of MEF2A has been associated with coronary artery disease (CAD) and myocardial infarction (MI). This deletion disrupts transcriptional activation, leading to endothelial dysfunction, which increases susceptibility to inflammation and atherosclerotic plaque formation, potentially resulting in thrombosis, MI, and sudden death (Wang2005Molecular). Another study identified a pro279leu variant in MEF2A, which was associated with a threefold increased risk of CAD/MI, suggesting it may be a genetic risk factor due to reduced transcriptional activity (Gonzalez2005The).

MEF2A mutations have also been linked to dilated cardiomyopathy (DCM). A novel heterozygous variation, NM_001365204.1: c.718G>T; p. (Gly240*), was identified in a family with DCM. This mutation results in the loss of transcriptional activity on target gene promoters, contributing to the pathogenesis of DCM (Qiao2020Detection). Overexpression of MEF2A in transgenic mice leads to dilated cardiomyopathy, characterized by ventricular dilation and sarcomeric disorganization, indicating that precise regulation of MEF2A is crucial for cardiac function (Xu2006Myocyte).

In Alzheimer's disease, decreased MEF2A expression due to enhancer methylation has been linked to impaired autophagy, suggesting a role in disease progression (Li2021Decreased).

## Interactions
MEF2A (myocyte enhancer factor 2A) is a transcription factor that engages in various protein-protein and protein-DNA interactions, playing a significant role in cardiac and muscle function. MEF2A interacts with the transcription co-activators CBP and p300, particularly binding to the p300 TAZ2 domain. This interaction is crucial for the assembly of enhanceosomes, which are complexes that facilitate transcriptional activation (He2011Structure). The interaction between MEF2A and p300 involves the MADS-box/MEF2 domain of MEF2A and a C-terminal region of p300, with the TAZ2 domain being necessary and sufficient for this binding (He2011Structure).

In cardiomyocytes, MEF2A interacts with STAT3, a transcription factor known for its cardioprotective roles. This interaction is dynamic and affects the transcriptional regulation of genes involved in inflammatory responses and cardiomyocyte survival (Moustafa2023The). MEF2A also forms complexes with HDAC1 and p300, acting as a scaffold protein in the regulation of SOD3 expression in THP-1 cells. This interaction is modulated by phosphorylation events and is crucial for the transcriptional activation of SOD3 (Ichihara2018The). These interactions highlight MEF2A's role in diverse cellular processes through its ability to engage with multiple partners.


## References


[1. (Guella2009Association) Ilaria Guella, Valeria Rimoldi, Rosanna Asselta, Diego Ardissino, Maura Francolini, Nicola Martinelli, Domenico Girelli, Flora Peyvandi, Marco Tubaro, Pier Angelica Merlini, Pier Mannuccio Mannucci, and Stefano Duga. Association and functional analyses of mef2a as a susceptibility gene for premature myocardial infarction and coronary artery disease. Circulation: Cardiovascular Genetics, 2(2):165–172, April 2009. URL: http://dx.doi.org/10.1161/circgenetics.108.819326, doi:10.1161/circgenetics.108.819326. This article has 27 citations and is from a peer-reviewed journal.](https://doi.org/10.1161/circgenetics.108.819326)

[2. (Gonzalez2005The) P Gonzalez. The pro279leu variant in the transcription factor mef2a is associated with myocardial infarction. Journal of Medical Genetics, 43(2):167–169, June 2005. URL: http://dx.doi.org/10.1136/jmg.2005.035071, doi:10.1136/jmg.2005.035071. This article has 39 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1136/jmg.2005.035071)

[3. (Santelli2000Crystal) Eugenio Santelli and Timothy J Richmond. Crystal structure of mef2a core bound to dna at 1.5 å resolution. Journal of Molecular Biology, 297(2):437–449, March 2000. URL: http://dx.doi.org/10.1006/JMBI.2000.3568, doi:10.1006/jmbi.2000.3568. This article has 148 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1006/JMBI.2000.3568)

[4. (Qiao2020Detection) Qi Qiao, Cui-Mei Zhao, Chen-Xi Yang, Jia-Ning Gu, Yu-Han Guo, Min Zhang, Ruo-Gu Li, Xing-Biao Qiu, Ying-Jia Xu, and Yi-Qing Yang. Detection and functional characterization of a novel mef2a variation responsible for familial dilated cardiomyopathy. Clinical Chemistry and Laboratory Medicine (CCLM), 59(5):955–963, December 2020. URL: http://dx.doi.org/10.1515/cclm-2020-1318, doi:10.1515/cclm-2020-1318. This article has 10 citations.](https://doi.org/10.1515/cclm-2020-1318)

[5. (Liu2014Requirement) Ning Liu, Benjamin R. Nelson, Svetlana Bezprozvannaya, John M. Shelton, James A. Richardson, Rhonda Bassel-Duby, and Eric N. Olson. Requirement of mef2a, c, and d for skeletal muscle regeneration. Proceedings of the National Academy of Sciences, 111(11):4109–4114, March 2014. URL: http://dx.doi.org/10.1073/pnas.1401732111, doi:10.1073/pnas.1401732111. This article has 220 citations.](https://doi.org/10.1073/pnas.1401732111)

[6. (Moustafa2023The) Amira Moustafa, Sara Hashemi, Gurnoor Brar, Jörg Grigull, Siemon H. S. Ng, Declan Williams, Gerold Schmitt-Ulms, and John C. McDermott. The mef2a transcription factor interactome in cardiomyocytes. Cell Death &amp; Disease, April 2023. URL: http://dx.doi.org/10.1038/s41419-023-05665-8, doi:10.1038/s41419-023-05665-8. This article has 9 citations.](https://doi.org/10.1038/s41419-023-05665-8)

[7. (Ichihara2018The) Mari Ichihara, Tetsuro Kamiya, Hirokazu Hara, and Tetsuo Adachi. The mef2a and mef2d function as scaffold proteins that interact with hdac1 or p300 in sod3 expression in thp-1 cells. Free Radical Research, 52(7):799–807, May 2018. URL: http://dx.doi.org/10.1080/10715762.2018.1475730, doi:10.1080/10715762.2018.1475730. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/10715762.2018.1475730)

[8. (Wu2010Structure) Yongqing Wu, Raja Dey, Aidong Han, Nimanthi Jayathilaka, Michael Philips, Jun Ye, and Lin Chen. Structure of the mads-box/mef2 domain of mef2a bound to dna and its implication for myocardin recruitment. Journal of Molecular Biology, 397(2):520–533, March 2010. URL: http://dx.doi.org/10.1016/j.jmb.2010.01.067, doi:10.1016/j.jmb.2010.01.067. This article has 40 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.jmb.2010.01.067)

[9. (Wang2005Molecular) Qing Wang. Molecular genetics of coronary artery disease. Current Opinion in Cardiology, 20(3):182–188, May 2005. URL: http://dx.doi.org/10.1097/01.hco.0000160373.77190.f1, doi:10.1097/01.hco.0000160373.77190.f1. This article has 126 citations and is from a peer-reviewed journal.](https://doi.org/10.1097/01.hco.0000160373.77190.f1)

[10. (He2011Structure) Ju He, Jun Ye, Yongfei Cai, Cecilia Riquelme, Jun O. Liu, Xuedong Liu, Aidong Han, and Lin Chen. Structure of p300 bound to mef2 on dna reveals a mechanism of enhanceosome assembly. Nucleic Acids Research, 39(10):4464–4474, January 2011. URL: http://dx.doi.org/10.1093/nar/gkr030, doi:10.1093/nar/gkr030. This article has 51 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/nar/gkr030)

[11. (Huang2000Solution) K. Huang. Solution structure of the mef2a-dna complex: structural basis for the modulation of dna bending and specificity by mads-box transcription factors. The EMBO Journal, 19(11):2615–2628, June 2000. URL: http://dx.doi.org/10.1093/emboj/19.11.2615, doi:10.1093/emboj/19.11.2615. This article has 80 citations.](https://doi.org/10.1093/emboj/19.11.2615)

[12. (Xu2006Myocyte) Jian Xu, Nanling L. Gong, Ilona Bodi, Bruce J. Aronow, Peter H. Backx, and Jeffery D. Molkentin. Myocyte enhancer factors 2a and 2c induce dilated cardiomyopathy in transgenic mice. Journal of Biological Chemistry, 281(14):9152–9162, April 2006. URL: http://dx.doi.org/10.1074/jbc.m510217200, doi:10.1074/jbc.m510217200. This article has 236 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m510217200)

[13. (Taylor2017Mef2) Michael V. Taylor and Simon M. Hughes. Mef2 and the skeletal muscle differentiation program. Seminars in Cell &amp; Developmental Biology, 72:33–44, December 2017. URL: http://dx.doi.org/10.1016/j.semcdb.2017.11.020, doi:10.1016/j.semcdb.2017.11.020. This article has 151 citations.](https://doi.org/10.1016/j.semcdb.2017.11.020)

[14. (Li2021Decreased) Hui Li, Feng Wang, Xuqi Guo, and Yugang Jiang. Decreased mef2a expression regulated by its enhancer methylation inhibits autophagy and may play an important role in the progression of alzheimer’s disease. Frontiers in Neuroscience, June 2021. URL: http://dx.doi.org/10.3389/fnins.2021.682247, doi:10.3389/fnins.2021.682247. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fnins.2021.682247)